^
Association details:
| Biomarker: | EZH2 mutation |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
126 | ANALYSIS OF EZH2 MUTATIONS IN SOLID AND LIQUID BIOPSY AND ITS ROLE AS PREDICTIVE BIOMARKER FOR CHEMOTHERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA
Published date:
06/09/2021
Excerpt:
We included 179 consecutive patients diagnosed with FL...our results shown that mutated EZH2 patients treated with R-bendamustine were significantly associated with inferior PFS (p = 0.013) (Figure 1A), unlike R-CHOP treated patients (p = 0.15)...
Secondary therapy:
bendamustine
Source:
Title:
M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy
Published date:
11/01/2018
Excerpt:
...439 patients with symptomatic/progressing indolent B-cell lymphoma (79% FL) randomized 1:1 to treatment with single rituximab or rituximab plus interferon-α2a...a FL patient cohort treated with first-line-immunotherapy only….Mutation in the gene EZH2 was associated with longer TTF and high-risk FLIPI with shorter OS.
DOI:
10.1182/blood-2018-99-117949
